Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.

Kaka N, Hafazalla K, Samawi H, Simpkin A, Perry J, Sahgal A, Das S.

Cancers (Basel). 2019 Nov 4;11(11). pii: E1723. doi: 10.3390/cancers11111723. Review.

2.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
3.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

4.

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.

Wang Y, Xing D, Zhao M, Wang J, Yang Y.

PLoS One. 2016 Mar 23;11(3):e0152170. doi: 10.1371/journal.pone.0152170. eCollection 2016. Review.

5.

Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.

Wu YS, Shui L, Shen D, Chen X.

Oncotarget. 2017 Feb 7;8(6):10703-10713. doi: 10.18632/oncotarget.12926. Review.

6.

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis.

Liao KL, Huang S, Wu YP.

Onco Targets Ther. 2018 Jun 19;11:3513-3520. doi: 10.2147/OTT.S156723. eCollection 2018.

7.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

8.

Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.

Fu P, He YS, Huang Q, Ding T, Cen YC, Zhao HY, Wei X.

Mol Clin Oncol. 2016 May;4(5):833-838. Epub 2016 Mar 10.

9.

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W.

Neuro Oncol. 2016 Sep;18(9):1313-8. doi: 10.1093/neuonc/now046. Epub 2016 Mar 22.

10.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

11.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

12.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
13.

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.

Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA.

Neuro Oncol. 2014 May;16(5):696-706. doi: 10.1093/neuonc/not236. Epub 2013 Dec 12.

15.

Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.

Zhou M, Yu P, Qu X, Liu Y, Zhang J.

PLoS One. 2013 Dec 4;8(12):e81858. doi: 10.1371/journal.pone.0081858. eCollection 2013.

16.

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML.

J Neurosurg. 2012 Feb;116(2):341-5. doi: 10.3171/2011.9.JNS11656. Epub 2011 Oct 28.

PMID:
22035272
17.

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.

Zhao YH, Wang ZF, Cao CJ, Weng H, Xu CS, Li K, Li JL, Lan J, Zeng XT, Li ZQ.

Front Neurol. 2018 Mar 21;9:127. doi: 10.3389/fneur.2018.00127. eCollection 2018.

18.

Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O.

J Neurosurg. 2015 May;122(5):1144-50. doi: 10.3171/2014.9.JNS14193. Epub 2015 Mar 13.

PMID:
25768833
19.

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.

Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF.

Neuro Oncol. 2018 Oct 9;20(11):1525-1535. doi: 10.1093/neuonc/noy064.

20.

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.

Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.

Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30.

Supplemental Content

Support Center